Public Comment No. 3-NFPA [ Sections 6.1.1, ]
|
|
- Darcy Lee
- 6 years ago
- Views:
Transcription
1 1 of 7 9/27/2016 2:41 PM Public Comment No. 3-NFPA [ Sections 6.1.1, ] Sections 6.1.1, * The medical evaluation of a candidate shall include a medical history, examination, and any laboratory tests required to detect physical or medical condition(s) that could adversely affect his/her ability to safely perform the essential job tasks outlined in I would like to ask that the new standard be very specific about the frequency of having exercise stress tests done by firefighters, and if the frequency needs to be increased at a certain age * This standard shall provide specific requirements for candidates based on medical conditions that can affect a candidate's ability to safely perform the essential job tasks of a fire fighter. Included in the specific blood test requirements I believe serum 25 hydroxy D should be included. My rationale for this is that many adults have a low vitamin D level. Obtaining sufficient vitamin D from natural food sources alone is difficult, and as a person ages, the skin does not synthesize vitamin D efficiently. Vitamin D is not only essential for bone health, but vitamin D status could affect cancer risk. Strong biological and mechanistic bases indicate that vitamin D plays a role in the prevention of colon, prostate, and breast cancers. Firemen are known to be at higher risk for cancers, and this would help protect them. Additionally, vitamin D is found in almost every cell in our bodies. A deficiency in this vitamin can mimic many illnesses, and hence prevent illnesses if a low level is detected and corrected. A growing body of research suggests that vitamin D. might play a role in the prevention and treatment of type 1 and type 2 diabetes, hypertension, glucose intolerance, multiple sclerosis and other medical conditions. Thank you very much for your consideration to add this to your annual blood tests. I have found that correcting a low serum vitamin D a critical means of helping an adult maintain optimum health. Thank you for all of your considerations! Caroline F. Hetfield, ANP-BC Adding a serum 25 hydroxy D test to the yearly blood tests will identify a low serum vitamin D level, <50 nmol/l, or <20ng/mL. Simple interventions to correct a low level will assure healthy bones and decrease the incidence of colon, prostate and breast cancers. Many adults have a low vitamin D level. Obtaining sufficient vitamin D from natural food sources alone is difficult, and as a person ages, the skin does not synthesize vitamin D efficiently. Additionally, vitamin D is found in almost every cell in our bodies. A deficiency in this vitamin can mimic many illnesses, and hence prevent illnesses if a low level is detected and corrected. A growing body of research suggests that vitamin D. might play a role in the prevention and treatment of type 1 and type 2 diabetes, hypertension, glucose intolerance, multiple sclerosis and other medical conditions. Clinically, I have found that correcting a low serum vitamin D a critical means of helping an adult maintain optimum health. First Revision No. 69-NFPA [Section No ] Submitter Full Name: Caroline Hetfield Organization: Fermilab
2 2 of 7 9/27/2016 2:41 PM Submittal Date: Thu Mar 31 14:21:47 EDT 2016 Committee Action: Rejected Resolution: The committee believes that this test in not within the scope of this chapter for candidates.
3 3 of 7 9/27/2016 2:41 PM Public Comment No. 4-NFPA [ Sections 6.1.1, ] Sections 6.1.1, * The medical evaluation of a candidate shall include a medical history, examination, and any laboratory tests required to detect physical or medical condition(s) that could adversely affect his/her ability to safely perform the essential job tasks outlined in * This standard shall provide specific requirements for candidates based on medical conditions that can affect a candidate's ability to safely perform the essential job tasks of a fire fighter. Specifying the frequency (and indication, if appropriate) for stress testing will help to standardize the yearly exams and assure that coronary artery disease is detected early for all firefighters. First Revision No. 69-NFPA [Section No ] Submitter Full Name: Caroline Hetfield Organization: Fermilab Submittal Date: Thu Mar 31 14:56:13 EDT 2016 Committee Action: Rejected Resolution: The committee believes that this is not necessary.
4 4 of 7 9/27/2016 2:41 PM Public Comment No. 12-NFPA [ New Section after ] TITLE OF NEW CONTENT Type your content here... Occupational Cancer Awareness Consultation The fire department physician shall, during the annual physical, inform the member of the heightened risks of acquiring various types of cancer associated with occupational exposures related to fire fighting, and shall make the member aware of common signs and symptoms of those cancers, and shall inform the member of practices that may limit exposure to known carcinogens. Occupational Stress Awareness Consultation The fire department physician shall, during the annual physical, inform the member of the heightened risks of stress associated with occupational exposures related to fire fighting, and shall make the member aware of common adverse signs and symptoms of occupational stress, and shall inform the member of practices that may limit the damaging effects of exposure to occupational stress, and to the best of his ability given the regional resources available, shall provide the member with references to licensed behavioral health specialists trained to recognize and treat stress related disorders in first responders. FD Physician shall incorporate cancer and stress awareness into consultation during annual evaluation to raise awareness to these hazards for fire fighters. Public Input No. 12-NFPA [Section No. A ] Submitter Full Name: Kurt Becker Organization: Clayton, Missouri Fire Department Affilliation: IAFF Submittal Date: Mon May 16 08:53:01 EDT 2016 Committee Rejected but see related SR Action: Resolution: SR-33-NFPA Statement: The committee agrees with the submitter that FD Physician shall incorporate cancer and stress awareness into consultation during annual evaluation to raise awareness to these hazards for fire fighters. They have made some modifications to the submission with the assistance of the submitter as Kurt is a TC member.
5 5 of 7 9/27/2016 2:41 PM Public Comment No. 2-NFPA [ Section No ] Physician Evaluation. Prosthetic cardiac valves compromise the member's ability to safely perform essential job task 8 if anticoagulation is required and essential job tasks 1, 4, 6, 7, and 9 if left ventricular dysfunction is present, and the physician shall report the applicable job limitations to the fire department. Member would be allowed to work on anticoagulants with a prosthetic cardiac valve per in the 2018 edition of NFPA 1582, to include essential job task 8. Per the proposed anticoagulants for NFPA 1582 edition, member would be allowed to work with a prosthetic valve and would not be disqualified. First Revision No. 6-NFPA [Section No ] Submitter Full Name: Shawn Rosalez Organization: Prince William County Fire and Rescue Submittal Date: Tue Mar 29 20:27:38 EDT 2016 Committee Action: Resolution: Rejected The committee has chosen to reject this comment as they believe that any level of anti-coagulation would significantly compromise the members ability to safely perform essential job function 8
6 6 of 7 9/27/2016 2:41 PM Public Comment No. 1-NFPA [ Section No ] Physician Evaluation. Full-dose or low-dose anticoagulation or any drugs that prolong prothrombin time, partial thromboplastin time, or international normalized ratio (INR) compromise the member's members ability to perform essential job task 8 due to the risk of internal bleeding from trauma with potential for rapid incapacitation from shock or central nervous system hemorrhage, and the physician shall report the applicable job limitations to the fire department, unless the member meets the following criteria: (1) Member is seen by a physician or clinic who is familiar and knowledgable about anticoagulant medication. (2) Prolong prothrombin time (PPT), partial thromboplastin time (PTT), or international normalized ratio (INR) has been controlled for a minmium of 1 year at therapeutic levels and is checked monthly once member returns to full duty. (3) Member is not taking any medications that would act adversely with his/her anticoagulant medication. (4) Member will also submit his/her PPT, PTT, or INR to his/her NFPA occupational physician for review during members annual physical. (5) Physician will look at the members medical history, current physical condition/characteristics, results from annual physical, dosage level of anticoagulant, and reason why anticoagulants have been prescribed to assess the members current well-being. (6) Member will wear a medical identification bracelet or necklace stating the member is on an anticoagulant, the type of anticoagulant and any known allergies. Members on Anticoagulant medications would be able to perform the 13 essential job tasks (job task 8) per NFPA 1582 provided they follow the criteria stated in and all parameters have been met. This would not make a binding/blanket statement for the Occupational Physician to follow, but allow him/her the ability to make a sound medical judgement based on the members current physical conditions and characteristics, medical history, and the dosage level of the anticoagulant. Anticoagulants are being used more and more frequently for Atrial Fibrillation (AFIB), Deep Vein Thrombosis, mechanical valves, and a multitude of other medical conditions and should be examined on a case by case basis. This new criteria would allow the Physicians to make sound medical decisions based on their medical experience and the physical, mental,emotional, and medical status of the member taking the anticoagulant medication. First Revision No. 6-NFPA [Section No ] Submitter Full Name: Shawn Rosalez Organization: Prince William County Fire and Rescue Submittal Date: Thu Mar 03 21:45:22 EST 2016 Committee Rejected
7 7 of 7 9/27/2016 2:41 PM Action: Resolution: The committee has chosen to reject this comment as they believe that any level of anti-coagulation would significantly compromise the members ability to safely perform essential job function 8.
VACo 2014 Achievement Award Entry. Prince William County Department of Fire and Rescue. Medical Physical Program
1 VACo 2014 Achievement Award Entry Prince William County Department of Fire and Rescue Abstract of the Program Prince William County's fire and rescue service is provided through a combination of career
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationPosition statement: Anti-coagulants and Risk Assessment
Position statement: Anti-coagulants and Risk Assessment Document information Protective marking: NOT PROTECTVELY MARKED Author: Matt Johnston Force/Organisation: College of Policing NPCC Coordination Committee
More informationFabrice Czarnecki, M.D., M.A., M.P.H., FACOEM I have no disclosures to make.
Maryland College of Occupational and Environmental Medicine April 2014 Fabrice Czarnecki, M.D., M.A., M.P.H., FACOEM fczarnecki@gablesgroup.com I have no disclosures to make. Guidelines 2006: Joint Task
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationPage 1 of 11 First Revision No. 10-NFPA 1583- [ Section No. 2.4 ] 2.4 References for Extracts in Mandatory Sections. NFPA 600, Standard on Industrial Fire Brigades, 2005 2010 edition. NFPA 1451, Standard
More informationReference Number: Revision No: Review Cycle:
Policy and Procedure for the management of patients presenting with excessive anticoagulation (INR>5.0) while on warfarin at the Cork University Hospital Group. Reference Number: Revision No: Review Cycle:
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationShawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists
Shawke A. Soueidan, MD Riverside Neurology & Sleep Specialists 757-221-0110 Epidemiology of stroke 2018 Affects nearly 800,000 people in the US annually Approximately 600000 first-ever strokes and 185000
More informationPUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Cofact 250 IU and 500 IU powder and solvent for solution for injection PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cofact contains
More informationSAVAYSA (edoxaban tosylate) oral tablet
SAVAYSA (edoxaban tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationPathophysiology. Tutorial 3 Hemodynamic Disorders
Pathophysiology Tutorial 3 Hemodynamic Disorders ILOs Recall different causes of thrombosis. Explain different types of embolism and their predisposing factors. Differentiate between hemorrhage types.
More informationTable of Contents. Early Identification Chart Biometric Screening Comprehensive Cardiovascular Disease Risk Assessment...
Public Safety Table of Contents Early Identification Chart... 1 Biometric Screening... 2 Comprehensive Cardiovascular Disease Risk Assessment.... 2 Recommended after Comprehensive Cardiovascular Disease
More informationA Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center.
A Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center Lauren Martens Abstract This study sought to determine the total number of
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter
ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task
More informationAugust 4, Dallas Fire-Rescue
August 4, 2008 Dallas Fire-Rescue Importance of the Program Protect DFR s #1 asset: Firefighters Improve the physical fitness of Firefighters Identify and treat the medical hazards of the profession: Increased
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #325: Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS
More informationTHERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%
Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION Edoxaban (Lixiana SERVIER Canada Inc.) Indication: Prevention of Stroke and Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationTreatment of the Medically Compromised Patient
Treatment of the Medically Compromised Patient Nashville Area Continuing Dental Education Series November 3, 2010 Harry J. Brown, MD Chief Medical Officer, Nashville Area Outline General Principles Specific
More informationNursing Process Focus: Patients Receiving Heparin
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC. Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
More informationCOURT OF APPEALS OF VIRGINIA
COURT OF APPEALS OF VIRGINIA Present: Judges Benton, Bray and Frank Argued at Chesapeake, Virginia DONALD R. GODFREY MEMORANDUM OPINION* BY v. Record No. 1950001 JUDGE JAMES W. BENTON, JR. APRIL 10, 2001
More informationTechnology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249
Dabigatran an etexilate for the preventionention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance Published: 15 March 2012 nice.org.uk/guidance/ta249 NICE 2012. All
More informationEliquis effect on inr prolongation 2017
Eliquis effect on inr prolongation 2017 The Borg System is 100 % Eliquis effect on inr prolongation 2017 Dec 17, 2016. Clin Chem Lab Med 2017; 55(8): e178 e180. Letter to the Editor. Tuukka A. Helin. prolongs
More informationQuality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationHeart on Fire: Infective Endocarditis. Objectives. Disclosure 8/27/2018. Mary McGreal DNP, RN, ANP-c, CCRN
Heart on Fire: Infective Endocarditis Mary McGreal DNP, RN, ANP-c, CCRN Objectives Discuss the incidence of infective endocarditis? Discuss the pathogenesis of infective endocarditis? Discuss clinical
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationExecutive Summary. This report provides the findings of a ten-month study requested by the Maryland
Executive Summary This report provides the findings of a ten-month study requested by the Maryland Department of Health and Mental Hygiene of a possible cancer cluster among fire fighters in Anne Arundel
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: ICU Stroke-Ischemic S/P tpa Version 2 5/29/14 This order set is designed to be used with an admission set or for a patient already admitted Nursing
More informationCARD 1: What is AFib and how does it relate to stroke? Talk to your patient about their condition and its connection to stroke.
4WARD CONVERSATION CARDS OVERVIEW Please find educational materials to facilitate shared decision making between you and your atrial fibrillation (AFib) patients. More information can be found at AFib4WARD.com.
More informationThe contractor establishes and maintains a register of patients with AF
Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently
More informationTHIS FORM IS TO BE COMPLETED BY CANDIDATE.
THIS FORM IS TO BE COMPLETED BY CANDIDATE. Information requested on this Candidate Pre-Placement Health Questionnaire ( Questionnaire ) is collected pursuant to Saudi Arabian Oil Company ( Saudi Aramco
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More information"Quality Professional Services Delivered with Compassion"
JULY/AUGUST 2013 A PUBLICATION OF THE MOBILE FIRE-RESCUE DEPARTMENT- ESTABLISHED 1888 INSIDE FEATURES Water Rescue & Survival Kudos Training Photos Firefighter Health "Quality Professional Services Delivered
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationTechnology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275
Apixaban for preventing enting stroke and systemic embolism in people with nonvalvular atrial fibrillation Technology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275 NICE 2018.
More informationUniversity Health System
Q University Health System Community Medicine Associates COMMUNITY MEDICINE ASSOCIATES PROTOCOL CMA PR 12-11.0204 Protocol For: Definition: Anticoagulation Management Protocol for MLP and PharmD To document
More information"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS"
"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS" ------------------------------------------------------------------------ LT J.D. Molinaro, DC, USN 11 August 2000 Introduction Any patient receiving
More informationStudent Outline. Improving Transportation Safety: Commercial Driver Medical Examiner Training CHAPTER 1. General FMCSA Information
Student Outline CHAPTER 1 General FMCSA Information FMCSA Mission Statement / Dedicated to Safety / NRCME Important Definitions Regulations Vs. Medical Guidelines Privacy and the Medical Examination 13
More informationbpac better e m dicine
INR Testing Quiz Feedback bpac nz better medicin e Contents INR Testing Quiz 2 Quiz Feedback: Responses from Colleagues, and Expert Review 4 bpac nz Review : Dr Janine Bailey, Motueka Dr Stephen Kuzmich,
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More information2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction
Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationCandidates sitting for the examination for licensure purposes in California should study and be familiar with the following test plan:
Candidates sitting for the examination for licensure purposes in California should study and be familiar with the following test plan: NHA Certified Phlebotomy Technician (CPT) CA-Specific Detailed Test
More informationADC TROMBOSEDIENST. Quality. The mission. The vision. The functioning of the ADC Thrombosis Service
ADC TROMBOSEDIENST Quality The mission The vision The functioning of the ADC Thrombosis Service Which INR is good, for how long do I have to take anticoagulant? Intensity 1 or 2 Frequency of taking an
More informationThe Role of Health Information Technology in Implementing Disease Management Programs
The Role of Health Information Technology in Implementing Disease Management Programs Donald F. Wilson, MD Medical Director Quality Insights of Pennsylvania May 11, 2006 Statewide Combined Topic Average
More informationSecond Revision No. 27-NFPA [ Global Comment ] Submitter Information Verification. Committee Statement. 1 of 41 9/27/2016 2:44 PM
1 of 41 9/27/2016 2:44 PM Second Revision No. 27-NFPA 1582-2016 [ Global Comment ] Everywhere in the document where it says CAT Scan, change it to CT Scan. Submittal Date: Wed Jul 13 16:15:36 EDT 2016
More informationAnalysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group
Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb Tro Kalayjian Chief Medical Analyst Chimera Research Group Prevalence of AFib in the US is expected to increase upwards of
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationCardiovascular Diseases and Diabetes
Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular
More informationManagement strategies for atrial fibrillation Thursday, 20 October :27
ALTHOUGH anyone who has had to run up a flight of steps or has had a frightening experience is quite familiar with a racing heartbeat, for the more than 2 million Americans who suffer from atrial fibrillation
More informationPrescribe appropriate immunizations for. Prescribe childhood immunization as per. Prescribe influenza vaccinations in high-risk
Supplemental Digital Appendix 1 46 Health Care Problems and the Corresponding 59 Practice Indicators Expected of All Physicians Entering or in Practice Infectious and parasitic diseases Avoidable complications/death
More informationAtrial fibrillation and anticoagulation therapy
Atrial fibrillation and anticoagulation therapy This leaflet offers more information about atrial fibrillation for patients who have been advised that they need anticoagulation therapy. If you have any
More informationInstruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy
Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationName: Date of stroke: Keyworker: Thomas Young Ward: of 10
Stroke Patient Handbook This leaflet offers more information about your stroke. If you have any further questions or concerns, please speak to the keyworker or staff member looking after you. Name: Date
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation Consensus Statement ~ October 2011 Contents 1 About 3 2 Introduction 5 3 Development of the consensus
More informationHearing Conservation Program
San José State University One Washington Square San José, California Facilities Development and Operations Department July 10, 2012 1) Purpose and Scope Hearing Conservation Program The University is dedicated
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION
More informationConsent for Testosterone Therapy-Men Revised 4/10/18
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
More informationDeep venous thrombosis and pulmonary embolism in joint replacement surgery
Deep venous thrombosis and pulmonary embolism in joint replacement surgery Even though joint replacement surgery is an effective procedure and in expert hands yields a low complication rate, deep venous
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationTechnology appraisal guidance Published: 25 July 2012 nice.org.uk/guidance/ta261
Rivaroxaban for the treatment of deep vein thrombosis and prevention ention of recurrent deep vein thrombosis and pulmonary embolism Technology appraisal guidance Published: 25 July 2012 nice.org.uk/guidance/ta261
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records Riccardo Miotto 1,2, Li Li 1,2, Brian A. Kidd 1,2, and Joel T. Dudley
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor NIKKI (Drospirenone and Ethinyl Estradiol Tablets USP) 3 mg/0.02 mg Lupin Limited Pithampur
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationReport on Comments A2006 Copyright, NFPA NFPA 1582 Report of the Committee on
Report of the Committee on Thomas Healy, Daisy Mountain Fire District, AZ [E] (Alt. to Steve L. Kreis) Fire Service Occupational Safety and Health James Johannessen, Underwriters Laboratories Incorporated,
More informationAlliance A Symptomatic brain radionecrosis after receiving radiosurgery for
RANDOMIZED PHASE II STUDY: CORTICOSTEROIDS + BEVACIZUMAB VS. CORTICOSTEROIDS + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES Pre-registration Eligibility Criteria Required Initial
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationMedical Examination Protocol for Police
Medical Examination Protocol for Police 1. Vision Monocular vision is likely to be disqualifying. See Exhibit A to the Firefighter protocol, which outlines the essential functions of the position. Far
More information14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationLUPIN LIMITED SAFETY DATA SHEET
LUPIN LIMITED SAFETY DATA SHEET Section 1: Identification Section 1, Identification Material Manufacturer Distributor Drospirenone and Ethinyl Estradiol Tablets USP 3 mg/0.03 mg Lupin Limited Pithampur
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More information